Intriguingly, approximately 20%–30% of patients with advanced-stage prostate cancer harbor genomic aberrations in the genes associated with the DNA damage and repair (DDR) pathway, the most notable being loss-of-function mutations in BRCA1/2 (3, 4). This evidence concerns the gene BRCA1 and prostate carcinoma.